Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | IGFBP5 | P24593 | 3/20 | 0.41 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889544 | 0.85 | GRM2 (0.43) | GRM2IGFBP5IGFBP3ADORA2AALOX15 | |
| SCHEMBL6893464 | 0.85 | GRM2 (0.45) | GRM2IGFBP5TAS2R14CYP3A4 | |
| SCHEMBL12803363 | 0.85 | ALOX15 (0.53) | GRM2KCNH2IGFBP5IGFBP3ALOX15 | |
| SCHEMBL6890674 | 0.81 | CHRM1 (0.49) | GRM2KCNH2 | |
| SCHEMBL17296540 | 0.81 | CHRM1 (0.56) | KCNH2 | |
| SCHEMBL2352500 | 0.78 | CHRM1 (0.54) | — | |
| SCHEMBL17583090 | 0.78 | GRM2 (0.46) | GRM2ADORA2AALOX15CYP3A4 | |
| SCHEMBL17656781 | 0.78 | CHRM1 (0.45) | GRM2 | |
| SCHEMBL2221819 | 0.76 | GRM2 (0.42) | GRM2ADORA2A | |
| SCHEMBL30744928 | 0.75 | GRM2 (0.43) | GRM2IGFBP5IGFBP3ADORA2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2512243-B1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2512243-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| CN-102651970-A | Quinoline amide m1 receptor positive allosteric modulators | MERCK SHARP & DOHME | 2012-08-29 | — | — | CN | disclosed |
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | GRM2 123/4885KCNH2 827/4885IGFBP5 3995/4885 |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | GRM2 124/4885KCNH2 838/4885IGFBP5 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.